Caribou Biosciences Inc (CRBU)

10:32 AM

Caribou Biosciences (NASDAQ:CRBU) Given New $8.00 Price Target at Citigroup - MarketBeat

10:32 AM

08:32 AM

Truist Securities reiterates Buy rating on Caribou Biosciences stock By Investing.com - Investing.com Nigeria

08:32 AM

04:55 AM

Published on: 2025-11-04 03:55:22 - newser.com

04:55 AM

04:52 AM

How to build a custom watchlist for Caribou Biosciences Inc.Bear Alert & AI Powered Buy/Sell Recommendations - newser.com

04:52 AM

03:47 AM

Statistical indicators supporting Caribou Biosciences Inc.’s strengthMarket Performance Summary & Risk Managed Trade Strategies - newser.com

03:47 AM

03:37 AM

Analyzing Caribou Biosciences Inc. with multi timeframe chartsWatch List & Reliable Price Breakout Alerts - newser.com

03:37 AM

03:33 AM

Comparing Caribou Biosciences Inc. in custom built stock radarsQuarterly Portfolio Review & Verified Momentum Watchlists - newser.com

03:33 AM

03:00 AM

What machine learning models say about Caribou Biosciences Inc.Earnings Risk Report & Community Verified Swing Trade Signals - newser.com

03:00 AM

01:42 AM

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel , an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - Investing News Network

01:42 AM

01:41 AM

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - Investing News Network

01:41 AM

Nov 03, 2025

Is Caribou Biosciences Inc. stock a contrarian buy2025 Winners & Losers & Safe Swing Trade Setup Alerts - newser.com

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - Stocktwits

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences to Participate in Upcoming Investor Conferences - The Manila Times

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences Stock Rises 3% After Dual Positive Phase 1 Trial Updates - Nasdaq

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy - Seeking Alpha

Nov 03, 2025

Nov 03, 2025

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga

Nov 03, 2025

Nov 03, 2025

Caribou Bio leaps on early data for vispa-cel - The Pharma Letter

Nov 03, 2025

Nov 03, 2025

CRBU: Citigroup Analyst Raises Price Target for Caribou Bioscien - GuruFocus

Nov 03, 2025

Nov 03, 2025

Alert inadvertently tagged to Caribou Biosciences withdrawn - MarketScreener

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - MSN

Nov 03, 2025

Nov 03, 2025

Ranking Caribou Biosciences Inc. among high performing stocks via toolsPortfolio Risk Summary & Verified Short-Term Trading Plans - newser.com

Nov 03, 2025

Nov 03, 2025

Is it time to cut losses on Caribou Biosciences Inc.Weekly Investment Recap & Smart Swing Trading Alerts - newser.com

Nov 03, 2025

Nov 03, 2025

Caribou Says Potential Non-Hodgkin Lymphoma Therapy Shows High Overall Response; Shares Rise Pre-Bell - MarketScreener

Nov 03, 2025

Nov 03, 2025

Will Caribou Biosciences Inc. stock go up soonMarket Activity Report & Fast Moving Trade Plans - newser.com

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences expects cash and marketable securities as of Sept 30 to be $159.2 million - MarketScreener

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences Reports Positive ANTLER Phase 1 Results - TipRanks

Nov 03, 2025

Nov 03, 2025

Using flow based indicators on Caribou Biosciences Inc.July 2025 Setups & Expert-Curated Trade Recommendations - newser.com

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences announces results from CaMMouflage Phase 1 trial - TipRanks

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - The Manila Times

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences stock soars after positive multiple myeloma therapy data By Investing.com - Investing.com UK

Nov 03, 2025

Nov 03, 2025

Why Caribou Biosciences Inc. stock remains on buy lists2025 Key Lessons & Free Accurate Trade Setup Notifications - newser.com

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences Soars Over 120%What's Driving The Rally? - Nasdaq

Nov 03, 2025

Nov 03, 2025

Caribou’s off-the-shelf CAR-T therapy shows promise in lymphoma study - statnews.com

Nov 03, 2025

Nov 03, 2025

Caribou Biosciences (NASDAQ: CRBU): 91% MRD negativity; CB-011 dose expansion planned - Stock Titan

Nov 03, 2025

Nov 03, 2025

Using Bollinger Bands to evaluate Caribou Biosciences Inc.2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com

Nov 03, 2025

Nov 03, 2025

Published on: 2025-11-03 00:52:40 - newser.com

Nov 03, 2025

Nov 03, 2025

Risk adjusted return profile for Caribou Biosciences Inc. analyzedJuly 2025 PostEarnings & Technical Confirmation Alerts - newser.com

Nov 03, 2025

Nov 02, 2025

Caribou Biosciences to Host Webcast Reporting New Clinical Data for Anti-CD19 and Anti-BCMA CAR-T Cell Therapies - Quiver Quantitative

Nov 02, 2025

Nov 02, 2025

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - The Manila Times

Nov 02, 2025